RAPS.org needs your explicit consent to store browser cookies. If you don't allow cookies, you may not be able to use certain features of the web site such as personalized content. Please see our Privacy Policy for more information.

Science & Technology: Pharmacogenomics and Pharmaceutical Development: Current Thinking and Regulatory Guidance

| 01 March 2008

Will pharmacogenomics truly become part of a much larger paradigm of personalized medicine, predicting the best possible treatment option in a regulatory framework designed to pick up adverse reactions much earlier in the pharmaceutical lifecycle?

© 2023 Regulatory Affairs Professionals Society.

Regulatory News

Story Thumbnail
Pharma official: Expect “substantial” revision of ICH stability and specification guidelines
- 27 March 2023
Read More
Story Thumbnail
FDA eases labeling, clarifies IVD requirements in COVID transition guidances
- 27 March 2023
Read More
Story Thumbnail
FDA encourages RCTs in accelerated approval guidance for oncology
- 27 March 2023
Read More

Discover more of what matters to you

No taxonomy

News »

EMA wants participants to serve on clinical trial multistakeholder forum

Pharma official: Expect “substantial” revision of ICH stability and specification guidelines

Books »

Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective

Risk Management Principles for Devices and Pharmaceuticals, Third Edition

Learning »

China Drug Registration and Reimbursement (On-Demand)

Sponsored Webcast: UK Drug and Device Approvals Post Brexit (on-demand)

Events »

Artificial Intelligence Summit

Combination Products Summit 2023